Roche

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Single kit consolidates three critical newborn screening panels for hospital labs

The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.

New York – September 21, 2026 -- Africa's push for greater control over its resources and a stronger voice in global governance took center stage as business leaders, heads of state, and investors gathered for the fifth edition of Unstoppable Africa, held alongside the 81st UN General Assembly session at the Marriott Marquis in Times Square.

Guterres calls for Africa's permanent UN Security Council seat

UN Secretary-General António Guterres told delegates that Africa needs a permanent presence on the UN Security Council to contribute to global dialogue and action. He urged reforms so the continent's critical minerals generate local value and jobs rather than being exported raw.

South San Francisco, Calif. – September 19, 2026 -- Dualitas Therapeutics has secured a research collaboration and license agreement with Roche worth up to $1 billion, including a $36.5 million upfront payment, to develop bispecific antibody therapeutics for immunology and inflammation diseases.

Dualitas will screen over 300,000 bispecific antibody combinations for Roche

Under the agreement, Dualitas will use its proprietary DualScreen Bispecific Discovery Engine to functionally screen more than 300,000 novel bispecific combinations, in what the company describes as one of the largest-scale bispecific discovery efforts undertaken. Roche will take over all subsequent preclinical development, regulatory, manufacturing and commercial activities for candidates that emerge from the collaboration.

Las Vegas – – September 15, 2026 -- The obesity therapeutics market across the seven major markets was valued at approximately USD 16 billion in 2025 and is projected to grow at a 27% CAGR through 2036, according to DelveInsight, as a wave of next-generation candidates threatens to disrupt the Eli Lilly-Novo Nordisk duopoly.

Oral GLP-1 Therapies Accelerate Patient Uptake

Novo Nordisk's oral WEGOVY surpassed 5 million cumulative U.S. prescriptions within 30 weeks of launch, while Eli Lilly's oral FOUNDAYO (orforglipron) gained significant traction among patients initiating obesity treatment by mid-2026. Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said FOUNDAYO's once-daily oral formulation positions it for rapid uptake as a more convenient alternative to injectable therapies.

SHERIDAN, WYOMING -- July 07, 2026 -- Roche announced positive results from the phase III Krascendo 1 study, showing that its investigational KRAS G12C inhibitor divarasib outperformed the approved first-generation inhibitors sotorasib and adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer. The study met both its primary and key secondary endpoints, with divarasib delivering statistically significant improvements in progression-free survival and overall survival. Roche plans to submit the data to health authorities and present full results at an upcoming medical meeting. The company positions the results as evidence that divarasib could become a new treatment standard for this genetically defined subgroup of lung cancer patients.

SHERIDAN, WYOMING -- June 15, 2026 -- The U.S. Food and Drug Administration has accepted Roche's supplemental Biologics License Application for Tecentriq and Tecentriq Hybreza in combination with chemotherapy as an adjuvant treatment for stage III dMMR/MSI-H colon cancer following surgery. The FDA has granted Priority Review and is expected to issue a decision by October 9, 2026. The filing is supported by Phase III ATOMIC study data showing a 50% reduction in the risk of disease recurrence or death compared to chemotherapy alone, results published in The New England Journal of Medicine.

SHERIDAN, WYOMING - May 13, 2026 - Roche has received CE Mark for Elecsys® pTau217, a blood-based diagnostic test designed to detect amyloid pathology associated with Alzheimer's disease, developed in collaboration with Eli Lilly and Company. The test measures phosphorylated Tau 217 protein from a routine blood draw and is intended to rule in or rule out amyloid pathology across both primary and secondary care settings using a single-assay design with unified cutoffs. The regulatory clearance positions Elecsys® pTau217 for deployment across Roche's installed base of laboratory instruments in CE mark-accepting countries, with potential FDA clearance in the United States under consideration for later this year.

SHERIDAN, WYOMING - March 13, 2026 - Roche has reported positive Phase II results for petrelintide, an amylin analog being developed for people living with overweight and obesity. According to the company, petrelintide delivered up to 10.7% mean body weight reduction at week 42 compared with 1.7% for placebo, with a p-value of less than 0.001. Roche also said the maximally effective dose showed placebo-like tolerability, with no vomiting cases and no treatment discontinuations due to gastrointestinal adverse events. For the obesity treatment market, the update is relevant because efficacy and tolerability remain central to prescribing, adherence and competitive positioning.